No Data
No Data
China Approves Zhejiang Huahai Pharmaceutical's Hypertension, Schizophrenia Drugs
Zhejiang Huahai Pharmaceutical (600521.SH): Enalapril Maleate Tablets Obtained Pharmaceutical Registration Certificate.
Zhejiang Huahai Pharmaceutical (600521.SH) announced that the company and its subsidiary, Changxing Pharmaceutical Co., Ltd. (abbreviated as Changxing Pharmaceutical, securities code: 835269), recently received the "Drug Registration Certificate" issued by the National Medical Products Administration. The name of the pharmaceutical is "Perindopril Maleate Tablet". Perindopril Maleate Tablet is mainly used to treat primary hypertension at all stages, renal vascular hypertension, various stages of heart failure, prevent symptomatic heart failure, and prevent coronary artery ischemic events in patients with left ventricular dysfunction.
Zhejiang Huahai Pharmaceutical Gets US FDA Approval for Chemotherapy Injection
Investors in Zhejiang Huahai Pharmaceutical (SHSE:600521) Have Seen Returns of 23% Over the Past Five Years
Huahai Pharmaceutical Gets US FDA Application Approval for Parkinson's Disease, Heart Failure, Diabetes Drugs
Huahai Pharmaceutical's H1 Profit Jumps 32% on Higher Operating Income
No Data
No Data